Abstract
Background: Activation of p38 mitogen-activated protein kinase (MAPK) plays an important role in developing ischemia / reperfusion (I/R) injury. FR167653 (FR) is a novel p38 MAPK inhibitor. In this study, we evaluated the effects of p38 MAPK inhibition during cold ischemia on subsequent reperfusion injury using FR as an additive to Euro-Collins (E-C) solution in canine lung transplantation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
